These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24865355)

  • 1. Growth inhibition effects of isoalantolactone on K562/A02 cells: caspase-dependent apoptotic pathways, S phase arrest, and downregulation of Bcr/Abl.
    Cai H; Meng X; Li Y; Yang C; Liu Y
    Phytother Res; 2014 Nov; 28(11):1679-86. PubMed ID: 24865355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression.
    Yang C; Yang J; Sun M; Yan J; Meng X; Ma T
    IUBMB Life; 2013 May; 65(5):435-44. PubMed ID: 23441067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isoalantolactone Inhibits Proliferation of K562/A02 Cells through Caspase-Dependent Apoptotic Pathway].
    Guan YH; Zhang XD; Cai H; Yang CH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):110-114. PubMed ID: 28245385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
    Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
    Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
    Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
    Cai H; He X; Yang C
    Phytother Res; 2018 Sep; 32(9):1764-1769. PubMed ID: 29701267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
    Amarante-Mendes GP; Naekyung Kim C; Liu L; Huang Y; Perkins CL; Green DR; Bhalla K
    Blood; 1998 Mar; 91(5):1700-5. PubMed ID: 9473236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
    Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
    Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
    Yin SS; Chen C; Liu Z; Liu SL; Guo JH; Zhang C; Zhang QW; Gao FH
    Cell Cycle; 2023 Jun; 22(12):1407-1420. PubMed ID: 37202916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells.
    Mao X; Yu CR; Li WH; Li WX
    Cell Res; 2008 Aug; 18(8):879-88. PubMed ID: 18663379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoalantolactone inhibits constitutive NF-κB activation and induces reactive oxygen species-mediated apoptosis in osteosarcoma U2OS cells through mitochondrial dysfunction.
    Di W; Khan M; Rasul A; Sun M; Sui Y; Zhong L; Yang L; Zhu Q; Feng L; Ma T
    Oncol Rep; 2014 Oct; 32(4):1585-93. PubMed ID: 25109871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
    Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.